Relationship between nitrogen mustard drug resistance in B-cell chronic lymphocytic leukemia (B-CLL) and protein expression of Bcl-2, Bax, Bcl-X and p53

Cancer Letters

Volumn 121, Issue 1, 1997, Pages 59-67

  Christodoulopoulos, G ^a   Fotouhi, N ^a   Krajewski, S ^b   Reed, J C ^b   Alaoui Jamali, M ^a   Panasci, L ^a  

^a MCGILL UNIVERSITY   (Canada)

^b BURNHAM INSTITUTE   (United States)

Author keywords

Apoptosis; Chronic lymphocytic leukemia; Drug resistance; Nitrogen mustards; p53

Indexed keywords

CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DNA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG RESISTANCE; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BLOTTING, WESTERN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LEUKEMIA, B-CELL, CHRONIC; MALE; MECHLORETHAMINE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

BRASSICACEAE;

EID: 0030816860     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(97)00336-4     Document Type: Article

References (30)

1. Biedler J.L. Drug resistance: genotype versus phenotype - thirty-second G.H.A. Clowes Memorial Award Lecture. Cancer Res. 54:1994;666-678.
2. Barry M.A., Behnke C.A., Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol. 40:1993;2353-2362.
3. Sen S., D'Incalci M. Apoptosis, biochemical events and relevance to cancer chemotherapy. FEBS Lett. 307:1992;122-127.
4. McConkey D.J., Aguilar-Santelesis M., Hartzell P., Erikson H., Millstedt S., Orremus S., Jondal M. Induction of DNA fragmentation in chronic B-lymphocytic leukemia cells. J. Immunol. 146:1991;1072-1076.
5. Bramson J., McQuillan A., Aubin R., Alaoui-Jamali M., Batist G., Christodoulopoulos G., Panasci L. Nitrogen mustard drug resistant B cell chronic lymphocytic leukemia as an in vivo model for crosslinking agent resistance. Mutat. Res. 336:1995;269-278.
6. Reed J.C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 124:1994;1-6.
7. Hokenbery D.M., Nunez G., Milliman C., Schreiber R.D., Korsmeyer S.J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 348:1990;334-336.
8. Oltvai Z., Milliman C., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:1993;609-619.
9. Sato T., Hanada M., Bodrug S., Irie S., Iwama M., Boise L.H., Thompson C.B., Golemis E., Fong L., Wang H.G.et al. Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system. Proc. Natl. Acad. Sci. USA. 91(20):1994;9238-9242.
10. Boise L.H., Gonzalez-Garcia M., Postema C.E., Ding L., Lindsten T., Turka A., Mao X., Nunez G., Thompson C.B. bcl-x, a bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell. 74:1993;597-608.
11. Caelles C., Helmberg A., Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature. 370:1994;220-223.
12. Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A., Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362:1993;847-849.
13. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of human bax gene. Cell. 80:1995;293-299.
14. El Rouby S.A., Thomas D.C., Rosenberg C.R., Potmesil M. p53 mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood. 82:1993;3452-3459.
15. Geleziunas R., McQuillan A., Malapetsa A., Hutchinson M., Kopriva D., Wainberg M.A., Hiscott J., Bramson J., Panasci L. Increased DNA synthesis and repair-enzyme expression in lymphocytes from patients with chronic lymphocytic leukemia resistant to nitrogen mustards. J. Natl. Cancer Inst. 83:1991;557-564.
16. Plumb J.A., Milroy R., Raye S.B. Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res. 49:1989;4435-4440.
17. J. Sambrook, E.F. Fritsch, T. Maniatis, Molecular Cloning, a Laboratory Manual, 2nd edn., Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989 pp. 18.60-18.74.
18. Krajewski S., Blomqvist C., Franssila K., Krajewska M., Wasenius V.M., Niskarien E., Nordling S., Reed J.C. Reduced expression of proapoptotic gene Bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 55(19):1995;4471-4478.
19. Blen N., Stafford D.M. A general method for isolation of high-molecular-weight DNA from eukaryotes. Nucleic Acids Res. 3:1976;2303-2308.
20. Suzuki Y., Sikiya T., Hayashi K. Allele-specific polymerase chain reaction: a method for amplification and sequence determination of a single component among a mixture of sequence variants. Anal. Biochem. 192:1991;82-84.
21. Sanger F., Nicklen S., Coulson A.R. DNA sequencing with chain terminating inhibitors. Proc. Natl. Acad. Sci. USA. 74:1977;5463-5467.
22. Krajewski S., Krajewska M., Shabaik A., Wang H.-G., Irue S., Fonh F., Reed J.C. Immunohistochemical analysis of in vivo pattern of Bcl-X expression. Cancer Res. 54:1994;5501-5507.
23. Kondo S., Yin D., Morimira T., Oda Y., Kikuch H., Takeuchi J. Transfection with a bcl-2 expression vector protects transplanted marrow from chemotherapy-induced myelosuppression. Cancer Res. 54:1994;2928-2933.
24. Thomas A., ElRouby S., Reed J.C., Krajewski S., Silber R., Potmesis J., Newcomb E.W. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia; relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogenes. 12:1991;1055-1062.
25. Kitada S., Bullrich F., Krajewski S., Zapata J., Anderson J., Hines J., Cassileth P., Croce C.M., Leo E., Reed J.C. Bcl-2 family genes, CPP32 protease, 13q14 deletions, and in vitro sensitivity to fludarabine and 2-chlorodeoxyadenosine in B-CLL: an ECOG study. Proc. Am. Assoc. Cancer Res. 38:1997;169.
26. J. Johnston, P. Daenick, K. Lee, G. Williams, L.G. Israels, M.R.A. Mowat, A. Begleiter, p53, MDM-2, Bax and Bcl-2 and drug resistance in chronic lymphocytic leukemia, Leukemia Lymphoma (1997) in press.
27. Levine A., Momand J., Finlay C.A. The p53 tumor suppressor gene. Nature. 351:1991;453-456.
28. Wattel E., Preudhomme C., Hecquet B., Vanrumbelele M., Quesnel B., Dervite I., Morel P., Fenaux P. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 84:1994;3148-3157.
29. Finlay C.A., Hinds P.W., Tan T.H., Eliyahu D., Oren M., Levine A.J. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half life. Mol. Cell. Biol. 8:1988;531-539.
30. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis (review). Cancer Res. 54:1994;4855-4878.